header logo es

NEWS

Immunonkologie bei Nierenkrebs verstehen: IKCC veröffentlicht neue Website auf Deutsch

Immunonkologie bei Nierenkrebs verstehen: IKCC veröffentlicht neue Website auf Deutsch

IKCC (International Kidney Cancer Coalition) hat mit www.10forIO.info eine neue Informationsplattform für Nierenkrebspatienten zum Thema Immunonkologie entwickelt: vertrauenswürdig, evidenzbasiert, patientenfreundlich und verständlich

Die International Kidney Cancer Coalition (IKCC) – in Deutschland vertreten durch Das Lebenshaus Nierenkrebs e.V. – hat den Launch einer neuen Internetseite bekannt gegeben: “10-for-IO” – Ten for immuno-oncology (englisch für „10 Fragen rund um Immunonkologie“). Diese neue Website steht nun auch auf Deutsch zur Verfügung und bietet umfassende Informationen zur Immunonkologie (IO), insbesondere bei Nierenkrebs. Bei der Immunonkologie handelt es sich um einen innovativen Therapieansatz, der derzeit bei verschiedenen Krebsarten einschließlich des metastasierten Nierenzellkarzinoms getestet wird. Sowohl bei den Ärzten als auch bei den Nierenkrebspatienten sind die Erwartungen an die Immunonkologie hoch. Ziel der neuen Website www.10forIO.info ist es daher, die vielen Fragen der Patienten weltweit zu beantworten. Gleichzeitig wird auf mögliche Fehlinformationen und überzogene Erwartungen, die im Rahmen der Medienberichterstattung oder in Online-Foren geweckt wurden, eingegangen.

Continue reading
28420 Hits

Checkmate 025: Immun- und zielgerichtete Therapie erfolgreich

Wien (APA) - Nierenzellkarzinome waren bis vor kurzem medikamentös kaum behandelbar. Die neuen Immuntherapeutika (z.B. Nivolumab) und auch ein Medikament der zielgerichteten Krebstherapie (Cabozantinib) bringen deutliche Überlebensvorteile für Patienten. Das geht aus zwei Studien hervor, die beim Europäischen Krebskongress (ECC) in Wien präsentiert und auch im New England Journal of Medicine publiziert wurden. Einen wesentlichen Fortschritt könnte die "CheckMate 025" Studie zeigen, welche die Wirksamkeit des derzeit "heißesten" Medikaments der Krebs-Immuntherapie - Nivolumab - bei Nierenkrebs belegen sollte. Die Studie wurde Anfang Juli 2015 gestoppt, weil die Behandlung mit dem neuen Medikament bereits eine signifikant höhere Überlebensrate der behandelten Patienten im Vergleich zur ebenfalls wirksamen etablierten Therapie mit dem mTOR-Inhibitor Everolimus zeigte. Letzteres wurde ehemals als Mittel zur Verhinderung der Abstoßungsreaktion bei Organtransplantationen entwickelt. Den ganzen Artikel lesen Sie hier: Immun- und zielgerichtete Therapie erfolgreich
Continue reading
27909 Hits

FDA approves Opdivo to treat advanced form of kidney cancer

The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. “Opdivo provides an important therapy option for patients with renal cell carcinoma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “It is one of few therapies that have demonstrated the ability to extend patients’ survival in treating this disease.” Torisel (temsirolimus), approved in 2007, is the only other FDA-approved therapy that has demonstrated overall survival in renal cell cancer. Renal cell carcinoma is the most common form of kidney cancer in adults and forms in the tissues of the kidney that make urine. The National Cancer Institute estimates 61,560 new cases and 14,080 deaths from kidney and renal pelvis cancer in the United States...

Checkmate 025: Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

The New England Journal of Medicine, just published the results of the Checkmate 025 phase III study, presented in part at the European Cancer Congress 2015 in Vienna. September 25, 2015. Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase III study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. Please read the full article in The New England Journal of Medicine: http://www.nejm.org/doi/full/10.1056/NEJMoa1510665#t=articleDiscussion  

Understanding immuno-oncology in kidney cancer: IKCC launches new website in response to strong demand from patients worldwide

Understanding immuno-oncology in kidney cancer: IKCC launches new website in response to strong demand from patients worldwide
IKCC (International Kidney Cancer Coalition) launches www.10forIO.info, a new web-based resource for kidney cancer patients: trusted, evidence-based, patient-focused and understandable.

Amsterdam/The Netherlands, September 25, 2015

b2ap3_thumbnail_IKCC_Logo_10-FOR-IO_RZ_2015_web.jpgThe International Kidney Cancer Coalition (IKCC) today announced the launch of a new internet platform “10-for-IO” – Ten for immuno-oncology (IO) – offering comprehensive information about immuno-oncology (IO), with a specific focus on kidney cancer. IO is an innovative therapeutic approach currently being tested in various types of cancer including metastatic renal cell carcinoma (mRCC). The prospect of immuno-oncology has raised high expectations among both the medical and the kidney cancer patient community. The new website “10-for-IO” (www.10forIO.info) aims to address many questions kidney cancer patients around the world are asking. The platform also tries to address potential misinformation and exaggerated expectations shown in the lay media and various online communities.

U.S. FDA Grants First Immuno-oncology Drug for kidney cancer breakthrough designation

Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma (RCC), according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor. The designation, which will expedite the development and review of nivolumab in RCC, is based on the CheckMate-025 trial. The phase III study was stopped early in July after an independent panel determined that nivolumab improved overall survival (OS) versus everolimus (Afinitor) in patients with advanced RCC. The CheckMate-025 data will be presented at the 2015 European Cancer Congress, according to BMS, which also announced its intent to file for regulatory approval this year. See more at: FDA grants nivolumab breakthrough designation in RCC

Scottish patients own cells to be used in cancer treatment trial

A PIONEERING new treatment for cancer which uses patients own cells to attack the disease is being trialled in Scotland. Authorisation has been granted for the research which will see patients suffering from three different kinds of cancer undergo the therapy. The treatment involves a type of white blood cell which naturally battles cancer, but which struggles to fight the disease when it starts taking hold. The cells are known as gamma delta T-cells. TC BioPharm chief executive Dr Michael Leek, whose Scottish company which has brought the treatment to the UK, said: “These cells are amazing because they have the ability to detect cells that have been transformed by cancer and then attack them and kill them.” In Japan, he said, they have been extracting gamma delta T-cells from patients, growing them in “massive numbers” in strict laboratory conditions, activating them so they are particularly aggressive and then injecting them...

Amsterdam Patient Charter for Global Kidney Cancer Care

Amsterdam Patient Charter for Global Kidney Cancer Care
The International Kidney Cancer Patient Charter was created by the International Kidney Cancer Coalition (IKCC) to ensure that the more than one million people living with kidney cancer worldwide (338 000 diagnoses in 2012 alone, have access to the best available treatment, care, information, and support. It is our aim to assist national kidney cancer patient organizations in helping patients and their families worldwide to obtain the information necessary to play an active role in the management of their kidney cancer and to gain a better awareness of what they can expect from their treatment and care. Read on: Amsterdam Patient Charter for Global Kidney Cancer Care The charter is now available in 14 languages: Global Patient charter  
Continue reading
29011 Hits